EICHORPublic-registry site landscape for NCT07703436, “Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease”, a Grade 2 IDH1-mutant Glioma study sponsored by Nuvation Bio Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07703436 (registry record) |
| Study title | Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease |
| Official title | A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease |
| Sponsor | Nuvation Bio Inc. |
| Condition(s) | Grade 2 IDH1-mutant Glioma; Grade 3 IDH1-mutant Glioma; Glioma; IDH1-mutant Glioma |
| Phase | PHASE2 |
| Listed sites | 0 |
| Intervention(s) | Safusidenib |
Patient-friendly overview of this study: eichor.com/study/NCT07703436.
Eichor generates a preliminary site-risk snapshot for NCT07703436 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
